



## Economic and Social Council

Distr.: General  
24 July 2013

Original: English

---

### Resumed substantive session for 2013

Agenda item 1

#### Adoption of the agenda and other organizational matters

### **Election of one member of the International Narcotics Control Board from among candidates nominated by Governments**

#### **Note by the Secretary-General**

1. The Secretary-General was informed by a letter dated 24 April 2013 of the resignation of Jorge Montaña (Mexico), a member of the International Narcotics Control Board, whose term of office was to expire on 1 March 2017.

2. Article 10, paragraph 5, of the Single Convention on Narcotic Drugs of 1961, as amended by the 1972 Protocol, reads as follows:

Where a vacancy occurs on the Board during the term of office of a member, the Council shall fill such vacancy as soon as possible and in accordance with the applicable provisions of article 9, by electing another member for the remainder of the term.

3. Since Mr. Montaña was re-elected by the Economic and Social Council in 2012 from among candidates nominated by Governments, the member to be elected to fill the remainder of the term should be elected from a list of candidates nominated by Governments.

4. In accordance with established procedure and the provisions of the Single Convention, the Secretary-General, in a note dated 6 May 2013, invited States Members of the United Nations and parties to the Single Convention that were not members of the United Nations to nominate candidates by 5 July 2013.



5. As at 5 July 2013, five candidates had been nominated by Governments. Their names are listed below:

Desmond Corrigan	Ireland
Aleksandr Konovalev	Belarus
Alejandro Mohar Betancourt	Mexico
Hossein Rahimi Soltanahmadi	Islamic Republic of Iran
Martin Sopuch	Slovakia

6. The biographical information that the Governments transmitted with their communications nominating the candidates is contained in annex I to the present note.

7. In accordance with article 9, paragraph 2, of the Single Convention, as amended by the 1972 Protocol, members of the Board shall not hold positions or engage in any activity that would be liable to impair their impartiality in the exercise of their functions. The positions and activities of the following persons are, in particular, incompatible with membership of the Board: persons who hold government posts, are in the paid service of their Governments or are acting under instructions from their Governments; persons who represent a Government at national or international forums on drug-related issues; and persons who are engaged in any activity, whether private or public, that could be likely to impair their impartiality in the exercise of their functions on the Board or that is in conflict with the functions of the Board.

8. Information on the meetings held by the Board in 2012 and 2013, current membership and payments made to members is contained in annex II to the present note.

## Annex I

### Biographical information on candidates nominated for election to the International Narcotics Control Board\*

#### 1. Desmond Corrigan (Ireland)

##### Education

BSc (Pharmacy), National University of Ireland; PhD, National University of Ireland.

##### Present post

Visiting Academic and Adjunct Assistant Professor at the School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, involving course work on drug misuse for the BSc (Pharmacy); MSc. in Community Pharmacy; MSc. in Pharmaceutical Manufacturing Technology and the Masters in Drug and Alcohol Policy (since 2008). Member of the Advisory Committee on Human Medicines of the Irish Medicines Board and Chairperson of its Traditional Herbal Medicines Subcommittee (since 2006).

##### Previous posts

Chairperson of the Horizontal Working Party on Drugs of the European Council of Ministers, Brussels (January-June 2013); Chair of the High-level Dialogues on Drugs with the Western Balkans and the United States of America (March 2013); Member of the Presidency Team at the Commission on Narcotic Drugs (March 2013); Member of the Interdepartmental Group on Drugs/Oversight Forum on Drugs (2005-2011); Chairperson of the National Advisory Committee on Drugs (2000-2011); Chairperson of the Horizontal Working Party on Drugs, Brussels (2004); Head of European Union Coordination at the forty-seventh session of the Commission on Narcotic Drugs (2004); Head of School of Pharmacy, Trinity College Dublin (1997-2003); Chairperson of the Scientific Committee and of the Risk Assessment Committee for New Synthetic Drugs (1997-2000/2012-2013); Representative of Ireland on the Scientific Committee of the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) (1994-2008); Vice-Chairperson, Scientific Committee, EMCDDA (1994-1997); Co-Chair, Scientific Committee of the European Scientific Cooperative on Phytotherapy (1991-2003); Lecturer/Senior Lecturer/Head, Department of Pharmacognosy, School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin (1966-2007).

##### Publications

Selected publications include EMCDDA Drug Profiles on Barbiturates, Benzodiazepines and Fentanyl; "Cannabis Pharmacology" in *EMCDDA Cannabis Monograph* (2008); *Facts about Drug Abuse in Ireland*, 4th ed. (Department of Health and Children, Dublin); *Natural Remedies — their origin and uses* (Taylor and Francis, London, 2001); "The in vitro metabolism of N-methyl-1-3-Benzodioscal-5-yl-2-aminobutane (MBDA) in the Rat", *Irish Journal of Medical*

---

\* Curricula vitae are issued without formal editing.

*Science*, vol. 168, No. 3 (1999); “Excretion profile of 4-Methylthioamphetamine in dogs”, *Pharmacy and Pharmacology Communications*, vol. 5 (1999).

### **Memberships and honours**

Lifetime Achievement Award at the National Pharmacy Awards (2009); European Scientific Cooperative on Phytotherapy Award for contributions to Phytotherapy (1994); Council of Europe Medical Fellowship (1987); Fellowship of the Pharmaceutical Society of Ireland (1984); Fellowship of the Linnean Society of London (1979).

### **Meetings attended**

Invited expert at meetings of the EMCDDA Risk Assessment Committee on BZP and on mephedrone (2010); Head of Delegation at the forty-seventh session of the Commission on Narcotic Drugs (2004); Co-Chair of the High-level Dialogue on Drugs between the European Union and the countries of Latin America and the Caribbean (2004), between the European Union and the Islamic Republic of Iran (2004) and between the European Union and the Andean Community (2004). Lectured frequently on Community Addiction Studies courses as well as to parents and community activists on drug issues. Was a technical adviser to the Social, Personal and Health Education Support Team working on the “Walk Tall” Drugs Prevention Programme for first-level schools and was involved in the training of many hundreds of first-level teachers in drug prevention. Performed a similar task in relation to support materials and training for second-level teachers implementing the “On my own two feet” programme in second-level schools. Interviewed regularly on national television, radio and for the print media on drugs issues, especially new psychoactive substances.

## **2. Aleksandr Konovalenko (Belarus)**

### **Education**

Psychiatric studies at the Grodno State Medical Institute in 1973.

### **Present post**

Doctor, psychiatrist and drug abuse treatment specialist for a special medical commission forming part of a health-care organization that provides drug abuse treatment services.

### **Previous posts**

Head Doctor, Grodno Province Clinical Centre for Psychiatry and Drug Abuse Treatment (2003-2012). Head Doctor, Grodno Province Drug Clinic (1982-2003). Chief organizer of assistance for drug abusers at the drug abuse treatment service, initially for the city of Grodno and subsequently for Grodno Province (from 1976). Departmental head at the Gaityunishki Grodno Province Psychiatric Hospital (from 1973). Other previous posts include chief consultant expert in drug abuse treatment at the Health-care Division of the Grodno Province Executive Committee, member of the National Council on Drug Abuse Treatment and of the Grodno Province Executive Committee's Inter-Agency Coordination Council for Drug Control and the Prevention of Drug Addiction.

### **Publications**

Main practical and research interests relate to the problems of providing assistance to persons dependent on psychoactive substances. Participated in the drafting of several State programmes to prevent the use of psychoactive substances. Co-author of a study guide for students entitled "Organization of drug abuse treatment services" and of two research articles published in medical journals.

### **Honours**

"Award for excellence in health care of the Republic of Belarus"; honorary awards from the Ministry of Health of Belarus and the Health-care Division of the Grodno Province Executive Committee.

### **Meetings attended**

Delegate to the first and second conferences of psychiatrists and drug abuse treatment specialists of Belarus; ninth conference of psychiatrists of the Russian Federation; World Health Organization's European Ministerial Conference on Mental Health (Helsinki, January 2005).

### 3. Alejandro Mohar Betancourt (Mexico)

#### Education

Doctor of Science in Epidemiology, Harvard University School of Public Health (1990); Master of Science in Epidemiology, Harvard University School of Public Health (1986); Visiting Fellow, Department of Pathology, Brigham & Women's Hospital, Boston, Massachusetts (1985-1989); Residency in anatomical pathology, "SUR system" (residency at the National Health Institutes, southern area, Mexico City) — Salvador Zubirán National Institute of Nutrition (1982-1985); Surgeon, Faculty of Medicine, National Autonomous University of Mexico (1976-1980).

#### Present post

Director General of the National Cancer Research Institute (since 2008).

#### Previous posts

Member of the Global Health Strategic Operations Advisory Group of the American Cancer Society (2009); Member of the Board of Governors of the National Autonomous University of Mexico (2008); Director General of the National Cancer Research Institute (2003-2008); "Edward Laroque Tinker" Visiting Professor, Stanford University (2000-2001); Director of Research at the National Cancer Research Institute (1999-2003); Deputy Director General of Research at the National Cancer Research Institute (1993-1999); Member of the Dissertation Committee for the Doctoral Programme of Medical Science of the Faculty of Medicine, Postgraduate Studies Division, Master's Degree and Doctorate Subdivision, National Autonomous University of Mexico (1993); Member of the Scientific Committee of the Mexican Association of Pathologists (1993-1995); Head of the Clinical Research Division, National Cancer Research Institute (1990-1993); Head of the Department of Epidemiology, National Cancer Research Institute (1988-1989); Teaching Fellow in Epidemiology, Harvard School of Public Health (1988-1990); Pathologist, Department of Pathology, National Cancer Research Institute (1985-1988).

#### Publications

Selected publications of a total of 173 national and international publications include "Intratypic changes of the E1 gene and the long control region affect ori function of human papillomavirus type 18 variants", in 94 *Journal of General Virology* 2013, 393-402; "Screening breast cancer. A commitment to Mexico (preliminary report)", in *Gaceta Mexicana de Oncología*, vol. 11, No. 4, July-August 2012, 220-227; "Impact of Diabetes and Hyperglycemia on Survival in Advanced Breast Cancer Patients", in *Experimental Diabetes Research*, 2012; "El Cáncer de Ovario. ¿El Nuevo reto en oncología ginecológica?" ["Ovarian cancer: the new challenge in gynaecological oncology?"], in 63 *Revista de Investigación Clínica* [Journal of Clinical Research] 6, 2011, 555-557; "Validation of the Mexican-Spanish version of the EORTC QLQ-C15-PAL questionnaire for the evaluation of health-related quality of life in patients on palliative care", 20 *Psycho-Oncology*, 2010, 889-896.

## Honours

Miguel Otero Award for Clinical Research, awarded by the General Health Council. April 2012; Member of the Group of the 300 Most Influential Leaders of Mexico; Recognition for participation in the meeting of the Global Health Strategic Operations Advisory Group of the American Cancer Society; awarded third place for best pharmacoeconomic work 2010 for the work entitled “Estudio farmacoeconómico en cáncer de mama. Análisis de costos en 633 pacientes tratadas en el Instituto Nacional de Cancerología, México, previos a la introducción de blancos moleculares terapéuticos” [“Pharmacoeconomic study on breast cancer: analysis of costs for 633 patients treated at the National Cancer Research Institute, Mexico, prior to the introduction of therapeutic molecular targets”], 7 June 2010, Mexican School of Pharmacoeconomics and International Society for Pharmacoeconomics and Outcomes Research Mexico Chapter; Member of the External Advisory Group for the Mexico Report on Social Determinants of Health. Coordination of the University Seminar on Social Issues. National Autonomous University of Mexico; Member of the jury for the Aaron Sáenz Annual Prize for Paediatric Research, awarded by the Federico Gómez Children’s Hospital of Mexico and the “General y Lic. Aarón Sáenz Garza, A.C” Association; Member of the Board of Arbitrators of the Faculty of Medicine, National Autonomous University of Mexico; Member of the Global Health Strategic Operations Advisory Group of the American Cancer Society; Certificate of Achievement for Dedication and Commitment to Establishing a National Cancer Plan for Mexico. American Cancer Society; Honourable mention, VII Aida Weiss Award. Work: “Neoplasia associated with type-one human immunodeficiency virus — a multidisciplinary endeavour”. National Autonomous University of Mexico.

## Meetings attended

Participated in 320 national and international conferences. Selected meetings include meetings of the American Society of Clinical Oncology; participation as lecturer in the Latin American Academic Conference on Cancer in Women, 4 December 2012, Carlos Slim Institute of Health, Catalan Institute of Oncology, Mexico City; participation in the XVII Annual Course for Volunteers, RETO, A.C. Total Recovery Group; participation in the Second Regional Medical Congress of Atlacomulco, “Timely Detection and Prevention of Cancer”, 18-20 October 2012; Coordinator of the conference “New concepts in low-grade lymphomas”, National Cancer Research Institute, 24 February 2012; Coordinator at the fifty-third Annual Congress of the Mexican Association of Pathologists, 30 April to 4 May 2011, Campeche, Mexico.

#### **4. Hossein Rahimi Soltanahmadi (Islamic Republic of Iran)**

##### **Education**

BSc Applied Chemistry (1995); MSc. Analytical Chemistry (candidate; to be completed by 31 July 2013 at the latest), Kharazmi University, Tehran.

##### **Present post**

Senior Expert for Controlled Substances, Food and Drug Organization, Ministry of Health and Medical Education, Islamic Republic of Iran (since 2002).

##### **Publications**

Control of Precursors (in Farsi, 2012); Good Manufacturing and Distribution Practice for Pharmaceutical Products (in Farsi, 2011).

##### **Honours**

Recipient of several Iranian Food and Drug Organization Meritorious Service Awards.

##### **Meetings attended**

Annual sessions of the Commission on Narcotic Drugs (2011, 2012 and 2013); Paris Pact Initiative, Second Expert Meeting Group on Precursors, New Delhi (November 2011); 8th International Training Course on Precursor Chemicals for Asian Narcotics Law Enforcement Officers, Bangkok (August 2011); Workshops on Pharmacovigilance and Drug Quality Control, Economic Cooperation Organization, Tehran (July 2010); conducted 16 Workshops on Precursor Chemical Control in Iranian Customs Offices (2012 and 2013).



## **5. Martin Sopuch (Slovakia)**

### **Education**

MBA in International Management, Thunderbird School of Global Management, United States of America (2006); MSc in Macroeconomic Policy, University of Bratislava (1996).

### **Present post**

Managing Director and Partner of Pharmagen GmbH, Pharmagen s.r.o., — Bratislava/Frankfurt am Main (since July 2010).

### **Previous posts**

Managing Director of AliPharm GmbH, Frankfurt am Main (1999-2010). Translator and Interpreter of the German language, Ministry of Defence (1998-1999); Export Manager, Slovakofarma a.s., Hlohovec, Slovakia (1996-1998).

### **Membership**

Founder and chairman of the charitable organization “Futbal for Kids”.

## Annex II

### Number, length and place of meetings, payments made to members and current membership of the International Narcotics Control Board

1. In accordance with article 11, paragraph 2, of the Single Convention on Narcotic Drugs of 1961, the Board shall meet as often as, in its opinion, may be necessary for the proper discharge of its functions, but shall hold at least two sessions in each calendar year.
2. The Board normally meets three times a year, each session lasting from one to three weeks. In 2012, the 103rd session was held from 30 January to 5 February 2012, the 104th session from 7 to 18 May 2012 and the 105th session from 30 October to 16 November 2012. In 2013, the 106th session was held from 4 to 8 February 2013 and the 107th session from 6 to 17 May 2013.
3. The sessions are normally held at the headquarters of the Board's secretariat, in Vienna (Vienna International Centre).
4. In accordance with General Assembly resolution 2491 (XXIII), the members of the Board receive a per diem allowance while participating in Board sessions or in official missions. As at January 2013, that allowance in Vienna was \$420 per day. Members' travel expenses are defrayed by the United Nations according to current administrative practice.
5. In accordance with General Assembly resolution [56/272](#), members of the Board receive an honorarium of \$1 per year.
6. The following are members of the Board, with terms of office expiring on 1 March of the year indicated:

Wayne Hall	Australia <sup>a</sup>	2017
David T. Johnson	United States of America	2017
Galina Aleksandrovna Korchagina	Russian Federation	2015
Marc Moinard	France	2015
Lochan Naidoo	South Africa	2015
Rajat Ray	India <sup>a</sup>	2015
Ahmed Kamal Eldin Samak	Egypt	2017
Werner Sipp	Germany	2017
Viroj Sumyai	Thailand	2015
Sri Suryawati	Indonesia <sup>a</sup>	2017
Francisco Thoumi	Colombia	2015
Raymond Yans	Belgium	2017
Vacant <sup>b</sup>		2017

<sup>a</sup> Member elected from among candidates nominated by the World Health Organization.

<sup>b</sup> Seat formerly occupied by Jorge Montaña (candidate nominated by Governments).